Closed |
S0528 |
Phase I Study of Lapatinib and Everolimus in Advanced Solid Tumors |
9/1/2006 |
8/25/2009 |
100% |
|
Published
|
Closed |
S0711 |
Dasatinib in patients with impaired hepatic function |
10/15/2008 |
|
100% |
|
|
Closed |
S1312 |
PI/II Inotuzumab + CVP for R/R CD22+ ALL |
4/1/2014 |
8/2/2019 |
100% |
|
|
Closed |
SWOG-8107 |
Management of Disseminated Melanoma, Master Protocol |
5/26/1982 |
11/15/1987 |
|
|
Published
|
Closed |
SWOG-8905 |
Phase II/III Study of Fluorouracil (5-FU) and its Modulation in Advanced Colorectal Cancer |
8/1/1989 |
1/1/1993 |
100% |
|
Published
|
Closed |
SWOG-8611 |
A Randomized Trial of Two Schedules of Trimetrexate Versus 5-Fluorouracil in Colorectal Carcinoma |
1/15/1987 |
11/15/1988 |
|
|
Published
|
Closed |
S0325 |
Phase IIb Imatinib or Dasatinib for Untreated Chronic CML |
8/15/2004 |
2/28/2009 |
100% |
|
Published
|
Closed |
S1400E |
Lung-MAP S1400E: HGF - Rilotumumab plus Erlotinib vs. Erlotinib |
6/15/2014 |
11/25/2014 |
3% |
|
|
Closed |
S1612 |
Older AML |
12/22/2017 |
|
5% |
|
|
Open |
S1918 |
Ph II/III study of R-miniCHOP +/- oral aza in elderly with newly diganosed DLBCL |
3/19/2021 |
|
23% |
|
|
Open |
S2012 |
II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab in Patients with Poorly Differentiated Extrapulmonary Small Cell NEC |
12/2/2021 |
|
23% |
|
|
Closed |
S1800D |
LUNGMAP S1800D: Non-match Sub-Study |
2/15/2022 |
3/10/2023 |
17% |
|
|
Closed |
SWOG-8819 |
ANCILLARY: Central Lymphoma Tissue Repository |
2/15/1989 |
|
|
|
Published
|
Closed |
SWOG-8855 |
Ancillary |
9/15/1990 |
9/1/2002 |
|
|
Published
|
Closed |
SWOG-8947 |
ANCILLARY: Central Lymphoma Serum Repository Protocol |
4/15/1990 |
|
|
|
|
Closed |
SWOG-9007 |
Cytogenetic Studies in Leukemia Patients |
7/15/1991 |
1/1/2012 |
|
|
Published
|
Closed |
SWOG-9205 |
Ancillary Prostate |
10/1/1992 |
10/1/2006 |
|
|
|
Closed |
SWOG-9218 |
Ancillary |
1/15/1993 |
4/1/2002 |
|
|
Published
|
Closed |
SWOG-9245 |
ANCILLARY: Central Lymphoma Tissue Repository for Relapsed or Recurrent Disease |
3/15/1993 |
|
|
|
|
Closed |
SWOG-9342 |
Cardiac Evaluation with MUGA scan at year 5-8 and year 10-11 OR at years 10-14 only |
2/15/1997 |
11/15/2003 |
43% |
|
Published
|